Explore the words cloud of the HAP2 project. It provides you a very rough idea of what is the project "HAP2" about.
The following table provides information about the project.
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
|Coordinator Country||France [FR]|
|Total cost||9˙996˙350 €|
|EC max contribution||9˙996˙350 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2020-01-01 to 2024-12-31|
Take a look of project's partnership.
|1||CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES||FR (NANTES)||coordinator||3˙642˙770.00|
|2||UNIVERSITAT ZURICH||CH (ZURICH)||participant||1˙510˙587.00|
|3||UNIVERSITE DE NANTES||FR (NANTES CEDEX 1)||participant||1˙273˙025.00|
|4||FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA||ES (BARCELONA)||participant||841˙365.00|
|5||STICHTING KATHOLIEKE UNIVERSITEIT||NL (NIJMEGEN)||participant||785˙000.00|
|6||NEUMEDICINES INC.||US (TUJUNGA CA)||participant||732˙127.00|
|7||BIG DATA SANTE||FR (NANTES)||participant||477˙328.00|
|8||UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN||US (ANN ARBOR)||participant||322˙837.00|
|9||HOSPICES CIVILS DE LYON||FR (LYON)||participant||315˙227.00|
|10||ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON||EL (ATHINA)||participant||96˙081.00|
“HAP2” aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of hospital-acquired pneumonia (HAP) and develop precision medicine in infectious diseases. HAP is an infectious disease of major concern in the world, and the most frequent cause of hospital-acquired infections with 500,000 episodes being treated every year in Europe. Despite the development of European recommendations, the incidence remains high, with dramatic medical consequences: existing therapies and preventive measures do not result in the expected favourable outcome (clinical cure and survival) for 30% of patients. HAP are moreover the main cause of antibiotic consumption in European hospitals and are increasingly induced by drug-resistant pathogens. New, alternative and more effective host-targeted strategies are therefore urgently needed to fight antibiotic resistance. The ambition of “HAP2” is to revolutionize the management of HAP: capitalising on the novel concept of critical-illness related immunosuppression altering the host-pathogens interactions, we propose a complete reappraisal of the physiopathology of HAP based on the concept of respiratory dysbiosis. “The HAP2” project will reach two ground-breaking objectives in the field of bacterial infections: first the development of host-targeted approaches for the prevention and the treatment of a severe bacterial infection through the supplementation of the IL-12/IFN-γ axis which is defective in patients at risk of pneumonia; second the development of a clinico-biological score based on an integrative assessment of the host-pathogen interactions and genetic variation, to predict the course of HAP and the response to treatment. Our interdisciplinary consortium, bringing together 10 partners from academia and industry with expertise in clinical trials, immunology, microbiome analysis, omics and social sciences is uniquely placed to achieve this ambition within this 5-year project.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HAP2" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HAP2" are provided by the European Opendata Portal: CORDIS opendata.